Anavex Life Sciences Bolsa (NASDAQ: AVXL)

Últimas noticias sobre Anavex Life Sciences (NASDAQ:AVXL) Bolsa

Anavex Life Sciences

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

AVXL

BLIN

BNRG

LMNR

QCOM

Aquí tienes cinco acciones estadounidenses que podrían llamar la atención de los inversores este lunes: LMNR, QCOM, AVXL, BNRG y BLIN.

5 acciones en el foco este lunes: LMNR, QCOM, AVXL, BNRG y BLIN

Anavex Life Sciences Corp. - Common Stock

Anavex Life Sciences Corp

Anavex Completes Phase 2 Enrollment For ANAVEX3-71 In Schizophrenia Treatment Study, Top Line Data Expected In Second Half Of 2025

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 40.8% to $1.32 during Monday's after-market session. The market value of their outstanding shares is at $231.0 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 8.77% to $0.77. The market value of their outstanding shares is at $61.6 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 8.29% to $2.48. The market value of their outstanding shares is at $6.1 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 7.9% to $0.09. The company's market cap stands at $1.3 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares moved upwards by 6.55% to $0.3. The market value of their outstanding shares is at $4.2 million. </li>
<li>Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) stock increased by 6.16% to $3.79. The market value of their outstanding shares is at $188.9 million. The company's, FY earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.6% to $8.37 during Monday's after-market session. The company's market cap stands at $712.2 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares decreased by 10.38% to $3.8. The market value of their outstanding shares is at $170.1 million. </li>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares fell 8.97% to $1.93. The market value of their outstanding shares is at $60.2 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares decreased by 8.53% to $0.33. The company's market cap stands at $10.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 7.31% to $8.5. The market value of their outstanding shares is at $232.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock declined by 6.95% to $2.41. The company's market cap stands at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AMIX

CTMX

CYCC

DBVT

FORA

GNFT

LIPO

ONCO

RLMD

TVGN

YMAB

12 Health Care Stocks Moving In Monday's After-Market Session

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that Marwan Noel Sabbagh, MD, Professor of Neurology at Barrow Neurological Institute and Chairman of Anavex's Scientific Advisory Board gave an oral presentation titled, "Oral Blarcamesine Novel Mechanism for Alzheimer Disease: Autophagy Restoration through Upstream SIGMAR1 Activation Clinical Efficacy Phase IIb/III Trial" at the 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East.
The ‘9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East' was held April 18-20, 2025 in Abu Dhabi, United Arab Emirates (UAE). The meeting convened clinicians including neurologists, psychiatrists, and geriatricians, nurses, public health workers, researchers, social workers, students, caregivers, and community advocates from the Middle East and North Africa (termed the MENA region), USA, Europe and other countries with an interest in epidemiology, clinical/research, medicine, basic science, and healthcare advocacy related to Alzheimer's disease and related disorders (ADRD) in the region. Specifically, an emphasis on region specific healthcare delivery were addressed.

Anavex Says Marwan Noel Sabbagh Presents Blarcamesine Phase IIb/III Findings At 9th International Conference On Alzheimer's Disease and Related Disorders in Middle East

Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) on Saturday announced that over three years of continuous treatment with blarcamesine (ANAVEX 2-73) demonstrated significant amelioration on clinical decline, showing continued clinically and meaningful benefit for early <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">Alzheimer&#8217;s disease patients</a>.
ATTENTION-AD (ANAVEX 2-73-AD-EP-004) trial result was presented at the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g44656765/anavex-life-sciences-announces-positive-up-to-4-years-oral-blarcamesine-results-from-phase-iibiii-" rel="noreferrer noopener">AD/PDTM&nbsp;2025 Conference</a>.
Continued blarcamesine treatment for up to four (4) years demonstrated a good comparative safety profile and no associated neuroimaging adverse events (no potentially fatal brain bleeding or brain swelling).
There were no deaths related to the study drug.
Blarcamesine-treated patients continue to accrue benefit through 4 years, as measured by the clinical endpoints ADAS-Cog13 and ADCS-ADL.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/40009941/neurodegenerative-disease-focused-anavex-life-sciences-alzheimers-candidate-slows-disease-progres" rel="noreferrer noopener">Neurodegenerative Disease-Focused Anavex Life Sciences&#8217; Alzheimer&#8217;s Candidate Slows Disease Progression By Almost 39%</a>
The delayed-start analysis for ADAS-Cog13 (assess cognitive function) showed a significant difference between the early start and late start treatment groups up to Week 192 (LS mean difference -3.83, P = 0.0165), favoring the early start group.
The results suggest that participants who initiated treatment with blarcamesine earlier in their disease progression showed greater cognitive function stability than those who did not initiate blarcamesine until ~1 year later.
In addition, an ADAS-Cog13 score difference between the treatment groups at Week 192 of more than 2 points is considered a clinically meaningful improvement.
Similarly, the delayed-start analysis for ADCS-ADL (functional evaluation scale) showed numerically favorable results for the early-start group over the late-start group up to Week 192. It reached statistical significance (LS mean difference +4.30, P = 0.0206).
With few or no interrupted treatment days, blarcamesine treatment resulted in an improved treatment effect for both cognition, ADAS-Cog13 (LS mean difference -4.20, P = 0.0083), and function, ADCS-ADL (LS mean difference +5.75, P = 0.0015) at Week 192.
Blarcamesine exhibited a favorable safety profile with the majority of adverse events (AEs) mild to moderate in severity (Grade 1 or 2), were predominantly linked to the initial titration phase, and could be managed with adjusted titration schedules.
Lastly, there are currently 74 participants receiving blarcamesine within the Compassionate Use Program, who continued treatment with blarcamesine subsequent completion of respective preceding open-label-extension studies from both ANAVEX 2-73-AD-EP-004 in early AD and from ANAVEX2-73-003 in mild-to-moderate AD.
Price Action: AVXL stock is down 1.71% at $8.05 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44651990/arvinas-touts-positive-data-from-potential-parkinsons-candidate-in-human-study-with-healthy-volunteers" target="_blank" rel="noreferrer noopener">Arvinas Potential Parkinson&#8217;s Treatment Shows Positive Data In Human Study</a></li>
</ul>
Photo by Berit Kessler via Shutterstock

Biotech

Health Care

General

Anavex Life Sciences Reports Prolonged Benefit Data Of Blarcamesine In Early Alzheimer's Over 3 Years

D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $46 price target.

Price Target

Analyst Ratings

D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) with a Buy and maintains $42 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $42 Price Target

ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference
Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and importance of early and continued long-term treatment of chronic Alzheimer's disease
Blarcamesine exhibited a favorable safety profile with no treatment-related deaths

Reported Saturday, Anavex Announces 4-Year Data For Oral Blarcamesine In Early Alzheimer's Disease, Showing Sustained Cognitive And Functional Benefit

A hotter-than-expected inflation report initially rattled markets on Wednesday morning, but investors found confidence to buy the dip, helping major indexes recover most losses by <a href="https://www.benzinga.com/government/regulations/25/02/43656846/inflation-rises-more-than-expected-in-january-chills-interest-rate-cut-hopes">midday trading in New York.</a>
The S&amp;P 500 was down 0.2%, while the Nasdaq 100 was flat, both rebounding from sharp declines following the January Consumer Price Index report. Small-cap stocks underperformed, with the Russell 2000 slipping 0.8%.
The headline CPI rose 3% year over year in January, surpassing both December's 2.9% reading and economist forecasts of 2.9%. On a monthly basis, inflation increased 0.5%, outpacing expectations of 0.3% and accelerating from December's 0.4% gain. This marked the fastest monthly inflation rate since August 2023.
Core inflation, which excludes food and energy, climbed to 3.3% year over year from 3.2% in December. On a monthly basis, core CPI increased 0.4%, exceeding estimates of 0.3% and doubling December's 0.2% rise.
Treasuries and interest rate markets reacted sharply to the inflation data. Traders scaled back expectations for Federal Reserve rate cuts, now projecting only one reduction by December 2025.
Treasury yields surged, reflecting heightened investor uncertainty. The 10-year Treasury yield jumped 10 basis points to 4.64%. The iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) fell 1%.
Despite rising Treasury yields and a stronger dollar, gold edged up 0.2% to $2,910 per ounce. Oil prices dropped 2% after reports that Donald Trump spoke with Russian President Vladimir Putin, fueling speculation about a potential ceasefire in Ukraine.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) also rebounded from earlier session losses.
<h3 class="wp-block-heading">Wednesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>21,688.40</td>
<td>0.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,056.85</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,411.00</td>
<td>-0.4%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,257.59</td>
<td>-0.8%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent020325&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;inched 0.2% down to $603.77.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was 0.4% down to $444.41.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;flattened at $528.09.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) eased 0.8% to $224.</li>
<li>The&nbsp;Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up 0.4%; the&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 1.2%.</li>
</ul>
Wednesday&#8217;s Stock Movers
<ul>
<li>Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) jumped more than 4% after the electric vehicle maker tumbled 6.3% on Tuesday, reaching oversold levels and extending its losing streak to five consecutive sessions.</li>
</ul>
Stocks reacting to company earnings reports included: 
<ul>
<li>CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>): up 15.7%</li>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>): up 4.5%</li>
<li>Edwards Lifesciences Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>): up 5.6%</li>
<li>América Móvil, S.A.B. de C.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMX#NYSE">AMX</a>): down 1.4%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>): up 0.2%</li>
<li>Energy Transfer LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ET#NYSE">ET</a>): up 0.3%</li>
<li>Southern Copper Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>): up 2.9%</li>
<li>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>): up 6.8%</li>
<li>Zillow Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/Z#NASDAQ">Z</a>): down 10.2%</li>
<li>CME Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>): up 2.2%</li>
<li>Chimera Investment Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIM#NYSE">CIM</a>): down 8.9%</li>
<li>Ryder System Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>): up 4.0%</li>
<li>Smurfit WestRock Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>): down 5.8%</li>
<li>Sonic Automotive Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>): down 2.4%</li>
<li>Alkermes Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>): up 4.1%</li>
<li>Anavex Life Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>): up 1.0%</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>): down 4.6%</li>
<li>Blackstone Mortgage Trust Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BXMT#NYSE">BXMT</a>): up 2.8%</li>
<li>Camtek Ltd/Israel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>): up 1.5%</li>
<li>Chefs' Warehouse Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHEF#NASDAQ">CHEF</a>): up 13.0%</li>
<li>Diebold Nixdorf Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DBD#NYSE">DBD</a>): down 3.2%</li>
<li>Dominion Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/D#NYSE">D</a>): up 0.6%</li>
<li>Exelon Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXC#NASDAQ">EXC</a>): up 0.4%</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43663963/record-high-egg-prices-drive-inflation-higher-in-january">Record-High Egg Prices Drive Inflation Higher In January</a></li>
</ul>
Illustration created using artificial intelligence via Midjourney.

Equities

Large Cap

Commodities

Economics

Federal Reserve

Tech

ETFs

$BTC

ALKS

BIIB

BXMT

CAMT

CHEF

SPDR Dow Jones Industrial Average ETF Trust

GILD

SCCO

SMCI

iShares Trust Barclays 20+ Year Treasury Bond Fund

TSLA

Select Sector SPDR-Consumer Discretionary

Stocks Trim Losses After Hot Inflation, Bonds Remain Pressured, Tesla Rebounds: What's Driving Markets Wednesday?

Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.19) by 26.32 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same period last year.

Anavex Life Sciences Q1 2025 GAAP EPS $(0.14) Beats $(0.19) Estimate, Cash And Cash Equivalents Of $120.8M At December 31, 2024, The Company Anticipates At Current Cash Utilization Rates And Ranges, A Runway Of Approximately 4 Years

ACRE

AEIS

AEMD

ALCO

AMWL

ASND

ASPN

ATRC

AYTU

BROS

CGNX

CNCK

CNDT

COOP

CRBG

CRSR

CRWS

CSCO

CTRE

CWST

DENN

EPRT

EQIX

FCPT

FSLY

GAIN

GILT

GLPG

GNRC

GOLD

GROW

HCSG

HOOD

HUBS

IREN

KRNT

MKSI

MLYS

MMLP

NMTC

OPRT

OTLY

PAYC

PEGA

PLMR

PODC

PXLW

PYPD

QDEL

QMCO

QTWO

Earnings Scheduled For February 12, 2025

Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent No. 12,180,174 entitled "A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF" from the United States Patent and Trademark Office (USPTO) for its U.S. Patent Application Serial Number USSN: 17/978,818. This new patent claims crystalline forms of the dihydrogen phosphate salt of ANAVEX&#xAE;2-73 (blarcamesine), freebase, transdermal patches and enteric coated oral dosage forms including the same for neuroprotection and treatment of neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease and other disorders.
Anavex's newest patent will be expected to remain in force at least until July 2039, not including any patent term extensions. It will expand and supplement the current ANAVEX&#xAE;2-73 (blarcamesine) patent portfolio, which includes several U.S. Patents, including U.S. Patent Nos. 10,413,519; 10,966,952; 11,661,405; and 11,498,908.

Government

Regulations

Anavex Secures New Patent for Alzheimer's Drug ANAVEX2-73, Extending Protection Through 2039

WIIM

Anavex Life Sciences shares are trading higher after the company revealed the publication of its peer-reviewed oral blarcamesine Phase IIb/III data in the Journal of Prevention of Alzheimer's Disease.

Anavex Life Sciences Reveals Peer-reviewed Publication Of Oral Blarcamesine Phase IIb/III Data In Journal Of Prevention Of Alzheimer's Disease

Legal

Press Releases

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease

Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer's Disease and Related Disorders in the Middle East

Management

Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board

Anavex Life Sciences to Participate in The Citizens Life Sciences Conference

Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Comments

Anavex Life Sciences

Noticias

Últimas noticias sobre Anavex Life Sciences (NASDAQ:AVXL) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL